Evaluation of the Effect of Citicoline and Docosahexaenoic Acid (DHA) on the Visual Function of Patients With Glaucoma

NCT05527106 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2022-09-02

No results posted yet for this study

Summary

Pilot, single-blind, randomized and controlled study to evaluate the changes produced in the visual function of patients with glaucoma after oral administration for 3 months of citicoline and docosahexaenoic Acid (DHA) vs citicoline and docosahexaenoic Acid (DHA) vs vitamin C.

Conditions

Interventions

DIETARY_SUPPLEMENT

Citicoline

Every subject randomized into this group have to take 2 sachets of Cebrolux 800 (362 mg of citicoline per day), every day, for 3 months.

DIETARY_SUPPLEMENT

Docosahexaenoic Acid (DHA)

Every subject randomized into this group have to take 3 pills of Brudypio 1.5g (1050 mg of DHA per day), every day, for 3 months.

DIETARY_SUPPLEMENT

Citicoline and Docosahexaenoic Acid (DHA)

Every subject randomized into this group have to take 2 sachets of Cebrolux 800 and 3 pills of Brudypio 1.5g per day, every day, for 3 months.

DIETARY_SUPPLEMENT

Vitamin C

Every subject randomized into this group have to take 1 pills of Vitamin C (500 mg per day), every day, for 3 months.

Sponsors & Collaborators

  • Institut Catala de Retina

    lead OTHER

Principal Investigators

  • Alfonso Anton, MD, PhD · Institut Catala de Retina

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-12
Primary Completion
2022-05-25
Completion
2022-05-25

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05527106 on ClinicalTrials.gov